Anzeige
Mehr »
Samstag, 29.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN5Q | ISIN: US91864C1071 | Ticker-Symbol: 2AB
Tradegate
27.08.26 | 14:21
0,635 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,6250,64528.08.
0,6150,66028.08.

Aktuelle News zur BARINTHUS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBarinthus Biotherapeutics plc. - 8-K, Current Report2
DiBarinthus Biotherapeutics plc: Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics12Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to...
► Artikel lesen
06.08.Barinthus Biotherapeutics plc. - 8-K, Current Report2
06.08.Barinthus Biotherapeutics plc: Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments12Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closingCompleted enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients...
► Artikel lesen
02.07.Barinthus Biotherapeutics plc. - 8-K, Current Report1
21.05.Barinthus Biotherapeutics plc. - 8-K, Current Report1
01.05.Barinthus BioTherapeutics GAAP EPS of -$0.1413
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
30.04.Barinthus Biotherapeutics in Green on Bringing Out Quarterly Numbers1
30.04.Barinthus Biotherapeutics plc: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments474Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with...
► Artikel lesen
30.04.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report-
30.04.Barinthus Biotherapeutics plc. - 8-K, Current Report1
22.04.Barinthus Biotherapeutics plc. - 8-K, Current Report-
31.03.Barinthus Biotherapeutics plc. - 8-K, Current Report-
13.03.Barinthus BioTherapeutics GAAP EPS of -$1.641
13.03.Barinthus Biotherapeutics plc. - 10-K, Annual Report2
13.03.Barinthus Biotherapeutics plc. - 8-K, Current Report2
07.11.25Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments275Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed...
► Artikel lesen
24.10.25ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Biotherapeutics251SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry...
► Artikel lesen
30.09.25Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases602GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1